George K. Ng - 12 Sep 2023 Form 3 Insider Report for Calidi Biotherapeutics, Inc. (CLDI)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
3
Accepted by SEC
25 Sep 2023, 18:39:10 UTC
Prior SEC filing
09 Aug 2023
Next SEC filing
10 Oct 2023
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
Wendy Pizarro, Attorney-in-fact for George Ng

Key filing fact

George K. Ng filed Form 3 for Calidi Biotherapeutics, Inc. (CLDI) on 25 Sep 2023.

Key facts

  • This page summarizes George K. Ng's Form 3 filing for Calidi Biotherapeutics, Inc. (CLDI).
  • 0 reported transactions and 6 derivative rows are listed below.
  • Accepted by SEC: 25 Sep 2023, 18:39.

Change

  • Previous filing in this sequence was filed on 09 Aug 2023.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

FLAG holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
18,542
Date
12 Sep 2023
Ownership
Direct
Footnotes
F1, F2
FLAG holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
9,550
Date
12 Sep 2023
Ownership
By Peng Ventures, LLC
Footnotes
F1, F2, F11

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

FLAG holding Derivative

Non-Qualified Stock Options (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
12 Sep 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
208,118
Exercise price
$1.80
Footnotes
F3, F4, F5
FLAG holding Derivative

Non-Qualified Stock Options (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
12 Sep 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
104,059
Exercise price
$1.80
Footnotes
F3, F4, F6
FLAG holding Derivative

Non-Qualified Stock Options (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
12 Sep 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
83,247
Exercise price
$2.40
Footnotes
F3, F4, F7
FLAG holding Derivative

Non-Qualified Stock Options (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
12 Sep 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
43,133
Exercise price
$7.11
Footnotes
F3, F4, F8
FLAG holding Derivative

Non-Qualified Stock Options (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
12 Sep 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
164,985
Exercise price
$7.11
Footnotes
F3, F4, F9
FLAG holding Derivative

Non-Qualified Stock Options (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
12 Sep 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
41,624
Exercise price
$7.11
Footnotes
F3, F4, F10
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 11 footnotes

Footnote F1

Reflects shares of common stock, par value $0.0001 per share (the "Common Stock"),of Calidi Biotherapeutics, Inc.(f/k/a First Light Acquisition Group, Inc.), a Delaware corporation ("New Calidi" or the "Issuer"). Pursuant to the Agreement and Plan of Merger, dated January 9, 2023, as amended on February 9, 2023 and June 16, 2023 (the "Merger Agreement"), by and among First Light Acquisition Group, Inc. ("FLAG"), FLAG Merger Sub, Inc. ("Merger Sub"), First Light Acquisition Group, LLC, Allan Camaisa and Calidi Biotherapeutics, Inc., a Nevada corporation ("Old Calidi"), on September 12, 2023, Merger Sub merged with and into Old Calidi, with Old Calidi surviving the merger as a wholly-owned subsidiary of the Issuer (such merger and the other transactions contemplated by the Merger Agreement, the "Business Combination"). Upon the consummation of the Business Combination, (the "Closing"), (cont'd. in FN 2)

Footnote F2

(cont'd. from FN 1) each share of common stock of Old Calidi (the "Old Calidi Common Stock") outstanding as of the time of the merger (the "Effective Time") converted into the right to receive approximately 0.41 share (the "Conversion Ratio") of the Issuer's Common Stock.

Footnote F3

The Reporting Person was originally granted Non-Qualified Stock Options by Old Calidi (the "Calidi Options"), which was assumed by the Issuer at the Effective Time and automatically converted into options exercisable for the Issuer's Common Stock (the "Assumed Options"), subject to the terms and conditions set forth in the Old Calidi 2016 Equity Incentive Plan, as amended from time to time, and the Old Calidi 2019 Equity Incentive Plan, as amended from time to time (together, the "Calidi Equity Incentive Plan"). Each Assumed Option has the right to acquire a number of shares of Issuer's Common Stock equal to (as rounded down to the nearest whole number) the product of (A) the number of shares of Old Calidi Common Stock subject to such Calidi Option immediately prior to the Effective Time, (cont'd in FN 4)

Footnote F4

(cont'd from FN 3) multiplied by (B) the Conversion Ratio; (1) at an exercise price equal to (as rounded up to the nearest whole cent) the quotient of (A) the exercise price of such Calidi Option immediately prior to the Effective Time, divided by (B) the Conversion Ratio; and (2) subject to the same vesting schedule as such Calidi Option. The exercise price and the number of shares of Issuer's Common Stock underlying the Assumed Options reflects the Conversion Ratio adjustment made in connection with the Closing.

Footnote F5

These Non-Qualified Stock Options were granted on May 9, 2019 in accordance with the terms and conditions of the applicable option agreement under the Calidi Equity Incentive Plan. These options are fully vested.

Footnote F6

These Non-Qualified Stock Options were granted on October 9, 2019 in accordance with the terms and conditions of the applicable option agreement under the Calidi Equity Incentive Plan. The options vest over four years as follows (i) 25% vesting on the one year anniversary of the grant date, and (ii) the remaining 75% of such shares vesting monthly in equal installments over the next three years, subject to the Reporting Person's continued service to the Issuer on each vesting date.

Footnote F7

These Non-Qualified Stock Options were granted on March 30, 2021 in accordance with the terms and conditions of the applicable option agreement under the Calidi Equity Incentive Plan. The options vest monthly in equal installments over a four year period from the grant date, subject to the Reporting Person's continued service to the Issuer on each vesting date.

Footnote F8

These Non-Qualified Stock Options were granted on February 1, 2022 in accordance with the terms and conditions of the applicable option agreement under the Calidi Equity Incentive Plan. The options vest monthly in equal installments over a four year period from the grant date, subject to the Reporting Person's continued service to the Issuer on each vesting date.

Footnote F9

These Non-Qualified Stock Options were granted on February 1, 2022 in accordance with the terms and conditions of the applicable option agreement under the Calidi Equity Incentive Plan. The options vest monthly in equal installments over a four year period from the grant date, subject to the Reporting Person's continued service to the Issuer on each vesting date.

Footnote F10

These Non-Qualified Stock Options were granted on February 1, 2022 in accordance with the terms and conditions of the applicable option agreement under the Calidi Equity Incentive Plan. The options vest over four years as follows (i) 25% vesting on the one year anniversary of the grant date, and (ii) the remaining 75% of such shares vesting monthly in equal installments over the next three years, subject to the Reporting Person's continued service to the Issuer on each vesting date.

Footnote F11

Directly held by Peng Ventures, LLC. Mr. Ng is the managing partner of Peng Ventures, LLC, and may be deemed to beneficially own the securities held by Peng Ventures, LLC. Mr. Ng disclaims beneficial ownership of any such securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

SEC remarks

Exhibit 24 - Power of Attorney

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .